Display options
Cite
Jayaraman S, Reid JM, Hawse JR, et al. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology. 2021;162(12)doi: 10.1210/endocr/bqab191.
Jayaraman, S., Reid, J. M., Hawse, J. R., & Goetz, M. P. (2021). Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology, 162(12), . https://doi.org/10.1210/endocr/bqab191
Jayaraman, Swaathi, et al. "Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside." Endocrinology vol. 162,12 (2021). doi: https://doi.org/10.1210/endocr/bqab191
Jayaraman S, Reid JM, Hawse JR, Goetz MP. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology. 2021 Dec 01;162(12). doi: 10.1210/endocr/bqab191. PMID: 34480554.
Copy Download .nbib Format: NLM
Share it on

Endocrinology. 2021 Dec 01;162(12). doi: 10.1210/endocr/bqab191.

Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.

Endocrinology

Swaathi Jayaraman, Joel M Reid, John R Hawse, Matthew P Goetz

Affiliations

  1. Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
  2. Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
  3. Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA.

PMID: 34480554 DOI: 10.1210/endocr/bqab191

Abstract

The selective estrogen receptor (ER) modulator, tamoxifen, is the only endocrine agent with approvals for both the prevention and treatment of premenopausal and postmenopausal estrogen-receptor positive breast cancer as well as for the treatment of male breast cancer. Endoxifen, a secondary metabolite resulting from CYP2D6-dependent biotransformation of the primary tamoxifen metabolite, N-desmethyltamoxifen (NDT), is a more potent antiestrogen than either NDT or the parent drug, tamoxifen. However, endoxifen's antitumor effects may be related to additional molecular mechanisms of action, apart from its effects on ER. In phase 1/2 clinical studies, the efficacy of Z-endoxifen, the active isomer of endoxifen, was evaluated in patients with endocrine-refractory metastatic breast cancer as well as in patients with gynecologic, desmoid, and hormone-receptor positive solid tumors, and demonstrated substantial oral bioavailability and promising antitumor activity. Apart from its potent anticancer effects, Z-endoxifen appears to result in similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with tamoxifen. In this review, we summarize the preclinical and clinical studies evaluating endoxifen in the context of breast and other solid tumors, the potential benefits of endoxifen in bone, as well as its emerging role as an antimanic agent in bipolar disorder. In total, the summarized body of literature provides compelling arguments for the ongoing development of Z-endoxifen as a novel drug for multiple indications.

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: [email protected].

Keywords: CYP2D6; antiestrogen; breast cancer; endoxifen; hormone therapy; tamoxifen

Publication Types

Grant support